Monte Rosa Therapeutics (NASDAQ:GLUE) Insider Sells $139,860.00 in Stock

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) insider Sharon Townson sold 6,000 shares of the company’s stock in a transaction on Monday, July 6th. The stock was sold at an average price of $23.31, for a total transaction of $139,860.00. Following the transaction, the insider owned 67,845 shares of the company’s stock, valued at $1,581,466.95. This trade represents a 8.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Sharon Townson also recently made the following trade(s):

• On Tuesday, June 23rd, Sharon Townson sold 3,000 shares of Monte Rosa Therapeutics stock. The shares were sold at an average price of $20.00, for a total value of $60,000.00.
• On Wednesday, June 17th, Sharon Townson sold 3,000 shares of Monte Rosa Therapeutics stock. The stock was sold at an average price of $19.00, for a total value of $57,000.00.

Monte Rosa Therapeutics Trading Up 4.9%

GLUE traded up $1.15 on Tuesday, reaching $24.40. The stock had a trading volume of 1,302,330 shares, compared to its average volume of 1,374,370. The company has a market capitalization of $2.06 billion, a price-to-earnings ratio of -16.49 and a beta of 1.56. Monte Rosa Therapeutics, Inc. has a fifty-two week low of $4.12 and a fifty-two week high of $25.77. The firm has a 50-day moving average of $19.43 and a 200-day moving average of $18.93.

Monte Rosa Therapeutics (NASDAQ:GLUE) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). The firm had revenue of $4.21 million for the quarter, compared to analyst estimates of $10.95 million. Monte Rosa Therapeutics had a negative net margin of 302.69% and a negative return on equity of 40.99%. Sell-side analysts anticipate that Monte Rosa Therapeutics, Inc. will post -1.23 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. GAMMA Investing LLC acquired a new position in shares of Monte Rosa Therapeutics in the 4th quarter valued at about $30,000. Russell Investments Group Ltd. acquired a new stake in Monte Rosa Therapeutics during the third quarter worth approximately $32,000. Lazard Asset Management LLC grew its stake in Monte Rosa Therapeutics by 42.9% during the second quarter. Lazard Asset Management LLC now owns 10,857 shares of the company’s stock worth $48,000 after purchasing an additional 3,262 shares during the period. Nisa Investment Advisors LLC increased its holdings in Monte Rosa Therapeutics by 16.7% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,151 shares of the company’s stock worth $49,000 after purchasing an additional 451 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in Monte Rosa Therapeutics by 32.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,164 shares of the company’s stock worth $50,000 after purchasing an additional 776 shares in the last quarter. 79.96% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have weighed in on GLUE. Wall Street Zen lowered shares of Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Guggenheim lifted their price target on shares of Monte Rosa Therapeutics from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. Weiss Ratings upgraded Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a report on Monday, May 11th. Wells Fargo & Company lowered their target price on Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a research report on Wednesday, March 18th. Finally, JPMorgan Chase & Co. lifted their target price on Monte Rosa Therapeutics from $30.00 to $31.00 and gave the stock an “overweight” rating in a report on Monday, May 11th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $33.33.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.